Comparing Levitra to Other ED Medications Like Viagra

Levitra’s Role in Combating Erectile Dysfunction (ED)
More Relevant Posts
Optimal Use of Levitra Tablets
Levitra’s Manufacturing Excellence
Where to participate

Not all possible drug interactions are listed here.

Side Effect	Frequency	Severity	Advice
Headache	Common	Mild	Take analgesics if needed
Flushing	Common	Mild	Stay hydrated
Nasal congestion	Less common	Mild	Use decongestants if necessary
Dizziness	Less common	Mild	Sit or lie down immediately

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Levitra only for the for the indication prescribed.

Levitra 20 mg Bayer can be part of a comprehensive ED management plan.
Regular check-ups are recommended for users on this medication.
Discontinue use and seek medical advice if adverse reactions occur.
Levitra may be ineffective if taken with high-fat meals.
Use with caution if you have any bleeding or clotting disorders.
The medication may interact with certain antifungal and antibiotic drugs.
Patients should inform their doctor about all current medications.
Timing of medication can influence the success of treatment.
Levitra 20 mg Bayer does not cause addiction or dependency.
The drug is often preferred for its rapid onset of action.
It’s important to have realistic expectations about the results.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Levitra 20 mg Bayer has a proven track record for efficacy.
It’s important to inform your doctor of any side effects experienced.
Lifestyle changes can improve ED alongside medication.
Risk factors for ED include diabetes, obesity, and smoking.
Consultation with a healthcare provider ensures safe use.
Levitra 20 mg Bayer is suitable for many but not all men.
Don’t share your medication with others to avoid misuse.
The tablet’s effects can be unpredictable if taken with certain foods.
Follow-up testing might be needed for underlying medical issues.
The medication is part of a comprehensive sexual health plan.
Use discretion and discretion when discussing medication use.

Efficacy of patients with LEVITRA treatmentdate_rangeTime Frame:After 6 monthsenhanced_encryptionNoSafety Issue: LEVITRA treatment improved the patient's erectiondate_rangeTime Frame:After 6 monthsenhanced_encryptionNoSafety Issue: LEVITRA improved the patient's erection after Minimum and Maximum Intervals between LEVITRA intake and the start of intercoursedate_rangeTime Frame:After 6 monthsenhanced_encryptionNoSafety Issue: Reporting a second successful intercourse within 24 hours of dosingdate_rangeTime Frame:After 6 monthsenhanced_encryptionNoSafety Issue: Patients prefer LEVITRA over last Erectile Dysfunction treatmentdate_rangeTime Frame:After 6 monthsenhanced_encryptionNoSafety Issue: Tolerability of patients with LEVITRA treatmentdate_rangeTime Frame:After 6 monthsenhanced_encryptionYesSafety Issue: )]TJ /C2_0 1 Tf 0 Tc 0 Tw 7.98 0 0 7.98 49.405 366.8227 Tm <004A>Tj /TT1 1 Tf 12 0 0 12 52.705 361.3027 Tm ( )Tj /TT0 1 Tf 0.0001 Tc -0.0001 Tw 0.28 0 Td ( Flexible dose studies started all )Tj 0 Tc 0 Tw 13.055 0 Td [(patients at LEVITRA 10 m)7.8 (g)-5 ( and allo)]TJ -0.0002 Tc -0.0005 Tw 14.83 0 Td (wed decrease in dose to 5 mg or )Tj 0.0001 Tc -0.0001 Tw -27.66 -1.145 Td (increase in dose to 20 mg based on side effects and efficacy. )Tj 0 Tc -0.0006 Tw -0.78 -1.655 Td (Back pain was reported in 2.0% of patients treated)Tj 0 Tw ( with LEVITRA and 1.7% of patients on placebo. )Tj 0.0001 Tc -0.0026 Tw 0 -1.315 TD (Placebo-controlled trials suggested )Tj 0.0002 Tc -0.001 Tw 14.25 0 Td (a dose effect in the incidence of)Tj 0.0004 Tc -0.0016 Tw 12.71 0 Td [( som)8.2 (e)-0.8 ( adverse events $headache, )]TJ -0.0003 Tw -26.96 -1.15 Td (flushing, dyspepsia, nausea, rhinitis$ over the )Tj 0.0001 Tc 0.0004 Tw 18.37 0 Td [(5 mg, 10 m)7.9 (g, and 20 m)7.9 (g doses of LEVITRA. The )]TJ 0.0008 Tc -0.0018 Tw -18.37 -1.15 Td [(f)3.8 (o)0.8 (llowing se)4.6 (ction identif)3.8 (i)-1.4 (es add)5.8 (ition)5.8 (a)4.6 (l, less f)3.8 (r)-1.2 (equ)5.8 (e)]TJ 0.001 Tc 19.99 0 Td [(nt events $<)5 (2%$ repo)6 (rte)4.8 (d)1 ( during th)6 (e clin)6 (ical )]TJ 0.0006 Tc -0.002 Tw -19.99 -1.15 Td [(developm)8.4 (ent of LEVITRA.

Levitra’s Role in Combating Erectile Dysfunction (ED)

Not all possible drug interactions are listed here. Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Levitra only for the for the indication prescribed. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. Efficacy of patients with LEVITRA treatmentdate_rangeTime Frame:After 6 monthsenhanced_encryptionNoSafety Issue: LEVITRA treatment improved the patient's erectiondate_rangeTime Frame:After 6 monthsenhanced_encryptionNoSafety Issue: LEVITRA improved the patient's erection after Minimum and Maximum Intervals between LEVITRA intake and the start of intercoursedate_rangeTime Frame:After 6 monthsenhanced_encryptionNoSafety Issue: Reporting a second successful intercourse within 24 hours of dosingdate_rangeTime Frame:After 6 monthsenhanced_encryptionNoSafety Issue: Patients prefer LEVITRA over last Erectile Dysfunction treatmentdate_rangeTime Frame:After 6 monthsenhanced_encryptionNoSafety Issue: Tolerability of patients with LEVITRA treatmentdate_rangeTime Frame:After 6 monthsenhanced_encryptionYesSafety Issue: )]TJ /C2_0 1 Tf 0 Tc 0 Tw 7.98 0 0 7.98 49.405 366.8227 Tm <004A>Tj /TT1 1 Tf 12 0 0 12 52.705 361.3027 Tm ( )Tj /TT0 1 Tf 0.0001 Tc -0.0001 Tw 0.28 0 Td ( Flexible dose studies started all )Tj 0 Tc 0 Tw 13.055 0 Td [(patients at LEVITRA 10 m)7.8 (g)-5 ( and allo)]TJ -0.0002 Tc -0.0005 Tw 14.83 0 Td (wed decrease in dose to 5 mg or )Tj 0.0001 Tc -0.0001 Tw -27.66 -1.145 Td (increase in dose to 20 mg based on side effects and efficacy. )Tj 0 Tc -0.0006 Tw -0.78 -1.655 Td (Back pain was reported in 2.0% of patients treated)Tj 0 Tw ( with LEVITRA and 1.7% of patients on placebo.

ScriptSave WellRx

)Tj 0.0001 Tc -0.0026 Tw 0 -1.315 TD (Placebo-controlled trials suggested )Tj 0.0002 Tc -0.001 Tw 14.25 0 Td (a dose effect in the incidence of)Tj 0.0004 Tc -0.0016 Tw 12.71 0 Td [( som)8.2 (e)-0.8 ( adverse events $headache, )]TJ -0.0003 Tw -26.96 -1.15 Td (flushing, dyspepsia, nausea, rhinitis$ over the )Tj 0.0001 Tc 0.0004 Tw 18.37 0 Td [(5 mg, 10 m)7.9 (g, and 20 m)7.9 (g doses of LEVITRA. The )]TJ 0.0008 Tc -0.0018 Tw -18.37 -1.15 Td [(f)3.8 (o)0.8 (llowing se)4.6 (ction identif)3.8 (i)-1.4 (es add)5.8 (ition)5.8 (a)4.6 (l, less f)3.8 (r)-1.2 (equ)5.8 (e)]TJ 0.001 Tc 19.99 0 Td [(nt events $<)5 (2%$ repo)6 (rte)4.8 (d)1 ( during th)6 (e clin)6 (ical )]TJ 0.0006 Tc -0.002 Tw -19.99 -1.15 Td [(developm)8.4 (ent of LEVITRA. Excluded from)8.4 ( this list ar)]TJ -0.0027 Tw 21.44 0 Td [(e those events that are infrequ)5.6 (e)4.4 (nt and m)8.4 (i)-1.6 (nor, )]TJ 0.0003 Tc -0.0009 Tw -21.44 -1.145 Td [(those events that m)8.1 (a)-0.9 (y be commonly observed in the )]TJ 0.0001 Tc -0.0013 Tw (absence of drug therapy, a)Tj 0.0003 Tc -0.0015 Tw 31.49 0 Td (nd those events that are )Tj -0.0001 Tc 0.0001 Tw -31.49 -1.155 Td (not reasonably associated with the drug. )Tj 0 Tc 0.0037 Tw 1.5 -1.315 Td (BODY AS A WHOLE: anaphylactic)Tj 0.0008 Tc -0.0015 Tw 14.775 0 Td [( reaction $in)5.8 (cluding lary)5.8 (ngeal edem)8.6 (a$, asthen)5.8 (ia, f)8.8 (ace edem)8.6 (a, )]TJ 0.0009 Tc 0 Tw -14.775 -2.3 Td (pain )Tj 0.0004 Tc -0.0004 Tw 0 -2.805 TD [(AUDITOR)-2.6 (Y)2.6 (: tinnitus )]TJ -0.0003 Tc 0.0003 Tw 0 -1.31 TD [(CARDIOVASCULAR:)-7.5 ( angina pectoris, ches)]TJ 0.0003 Tc -0.0003 Tw 18.11 0 Td [(t pain, hypertension, hypotension, m)8.1 (yocardial )]TJ 0.0005 Tc -0.0005 Tw -18.11 -1.155 Td [(ischem)8.3 (ia, myocardial inf)8.5 (a)-0.7 (rction, palpitation, )]TJ -0.0001 Tc 0.0001 Tw 17.97 0 Td (postural hypotension, s)Tj 0 Tc 0 Tw 9.245 0 Td (yncope, tachycardia )Tj 0.0002 Tc -0.0002 Tw -27.215 -1.31 Td [(DIGESTIVE: abdom)8 (inal pain, abnorm)8 (al liver f)]TJ -0.0027 Tw 18.88 0 Td [(unction tests, diarrhea, dry )-7.5 (m)8 (outh, dysphagia, )]TJ 0.0005 Tc -0.003 Tw -18.88 -1.155 Td [(esophagitis, gastritis, gas)4.7 (t)-1.7 (roesophag)5.5 (e)]TJ 0.0006 Tc -0.0006 Tw 14.83 0 Td [(al reflux, G)7.8 (G)2.8 (TP increas)4.8 (ed, vom)8.4 (iting )]TJ 0.0004 Tc -0.0004 Tw -14.83 -1.32 Td (MUSCULOSKELETAL: arthra)Tj 0.0005 Tc -0.0025 Tw 12.805 0 Td (lgia, back pain, myalgia, neck pain )Tj 0.0001 Tc -0.0017 Tw -12.805 -1.315 Td [(NERVOUS:)-7.1 ( hypertonia, hypesthesia, insom)7.9 (nia)]TJ 0.0002 Tc 18.855 0 Td [(, paresthesia, som)8 (nolence, vertigo )]TJ 0.0004 Tc -0.0004 Tw -18.855 -1.315 Td (RESPIRATORY: dyspnea, ep)Tj -0.0003 Tc 0.0003 Tw 12.09 0 Td (istaxis, pharyngitis )Tj 0 Tc 0.0016 Tw -12.09 -1.32 Td (SKIN AND APPENDAGES: photosensitivity)Tj 0.0002 Tc -0.0014 Tw 18.42 0 Td ( reaction, pruritus, rash, sweating )Tj ET q 1 0 0 1 -8.195038 -34.037292 cm /CS0 CS 0.004 0.004 0.004 SCN 0.75 w 1 j 1 J q 1 0 0 1 61.2 652.08 cm 0 0 m 432 0 l 0.48 -22.68 m 432.48 -22.68 l 0.48 -60.3 m 432.48 -60.3 l 0 -203.7 m 432 -203.7 l S Q Q /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 201 0 obj <>>>/Resources 234 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA. ) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 202 0 obj <>>>/Resources 236 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 236 0 obj <> endobj 237 0 obj <> endobj 235 0 obj <>stream �5H�8CTzd#E��[��w��ᮆ�)ȼ�7�)��ࢠ1�97��8��{�s ��~�N�4T$�C#A�}�A�_��r�y��XXm�d�=��jc��}�jˇX��(��? Excluded from)8.4 ( this list ar)]TJ -0.0027 Tw 21.44 0 Td [(e those events that are infrequ)5.6 (e)4.4 (nt and m)8.4 (i)-1.6 (nor, )]TJ 0.0003 Tc -0.0009 Tw -21.44 -1.145 Td [(those events that m)8.1 (a)-0.9 (y be commonly observed in the )]TJ 0.0001 Tc -0.0013 Tw (absence of drug therapy, a)Tj 0.0003 Tc -0.0015 Tw 31.49 0 Td (nd those events that are )Tj -0.0001 Tc 0.0001 Tw -31.49 -1.155 Td (not reasonably associated with the drug. )Tj 0 Tc 0.0037 Tw 1.5 -1.315 Td (BODY AS A WHOLE: anaphylactic)Tj 0.0008 Tc -0.0015 Tw 14.775 0 Td [( reaction $in)5.8 (cluding lary)5.8 (ngeal edem)8.6 (a$, asthen)5.8 (ia, f)8.8 (ace edem)8.6 (a, )]TJ 0.0009 Tc 0 Tw -14.775 -2.3 Td (pain )Tj 0.0004 Tc -0.0004 Tw 0 -2.805 TD [(AUDITOR)-2.6 (Y)2.6 (: tinnitus )]TJ -0.0003 Tc 0.0003 Tw 0 -1.31 TD [(CARDIOVASCULAR:)-7.5 ( angina pectoris, ches)]TJ 0.0003 Tc -0.0003 Tw 18.11 0 Td [(t pain, hypertension, hypotension, m)8.1 (yocardial )]TJ 0.0005 Tc -0.0005 Tw -18.11 -1.155 Td [(ischem)8.3 (ia, myocardial inf)8.5 (a)-0.7 (rction, palpitation, )]TJ -0.0001 Tc 0.0001 Tw 17.97 0 Td (postural hypotension, s)Tj 0 Tc 0 Tw 9.245 0 Td (yncope, tachycardia )Tj 0.0002 Tc -0.0002 Tw -27.215 -1.31 Td [(DIGESTIVE: abdom)8 (inal pain, abnorm)8 (al liver f)]TJ -0.0027 Tw 18.88 0 Td [(unction tests, diarrhea, dry )-7.5 (m)8 (outh, dysphagia, )]TJ 0.0005 Tc -0.003 Tw -18.88 -1.155 Td [(esophagitis, gastritis, gas)4.7 (t)-1.7 (roesophag)5.5 (e)]TJ 0.0006 Tc -0.0006 Tw 14.83 0 Td [(al reflux, G)7.8 (G)2.8 (TP increas)4.8 (ed, vom)8.4 (iting )]TJ 0.0004 Tc -0.0004 Tw -14.83 -1.32 Td (MUSCULOSKELETAL: arthra)Tj 0.0005 Tc -0.0025 Tw 12.805 0 Td (lgia, back pain, myalgia, neck pain )Tj 0.0001 Tc -0.0017 Tw -12.805 -1.315 Td [(NERVOUS:)-7.1 ( hypertonia, hypesthesia, insom)7.9 (nia)]TJ 0.0002 Tc 18.855 0 Td [(, paresthesia, som)8 (nolence, vertigo )]TJ 0.0004 Tc -0.0004 Tw -18.855 -1.315 Td (RESPIRATORY: dyspnea, ep)Tj -0.0003 Tc 0.0003 Tw 12.09 0 Td (istaxis, pharyngitis )Tj 0 Tc 0.0016 Tw -12.09 -1.32 Td (SKIN AND APPENDAGES: photosensitivity)Tj 0.0002 Tc -0.0014 Tw 18.42 0 Td ( reaction, pruritus, rash, sweating )Tj ET q 1 0 0 1 -8.195038 -34.037292 cm /CS0 CS 0.004 0.004 0.004 SCN 0.75 w 1 j 1 J q 1 0 0 1 61.2 652.08 cm 0 0 m 432 0 l 0.48 -22.68 m 432.48 -22.68 l 0.48 -60.3 m 432.48 -60.3 l 0 -203.7 m 432 -203.7 l S Q Q /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 201 0 obj <>>>/Resources 234 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA. ) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 202 0 obj <>>>/Resources 236 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 236 0 obj <> endobj 237 0 obj <> endobj 235 0 obj <>stream �5H�8CTzd#E��[��w��ᮆ�)ȼ�7�)��ࢠ1�97��8��{�s ��~�N�4T$�C#A�}�A�_��r�y��XXm�d�=��jc��}�jˇX��(��?

Product	Dosage	Quantity + Bonus	Price
Levitra Soft Tabs	20mg	20 Pills	74.68€ 71.12€
Levitra Generic	20mg	30 + 4 Pills	70.59€ 67.23€
Levitra Original	20mg	48 + 4 Pills	235.14€ 223.94€
Levitra Generic	40mg	20 Pills	67.56€ 64.34€
Levitra Soft Tabs	20mg	180 + 10 Pills	398.14€ 379.18€
Levitra Generic	60mg	20 Pills	81.30€ 77.43€
Levitra Generic	60mg	90 + 6 Pills	291.82€ 277.92€
Levitra Original	20mg	120 + 8 Pills	528.19€ 503.04€
Levitra Original	20mg	34 + 2 Pills	188.51€ 179.53€
Levitra Generic	10mg	20 Pills	46.54€ 44.32€
Levitra Original	20mg	14 + 2 Pills	102.27€ 97.40€

Proportion of vardenafil subjects with a 50% or greater decrease from baseline in mean sperm concentration at 6 months (LOCF), compared to placebo after repeated usedate_rangeTime Frame:24 weeksenhanced_encryptionyesSafety Issue: Mean sperm concentrationdate_rangeTime Frame:24 weeksenhanced_encryptionyesSafety Issue: Mean sperm countdate_rangeTime Frame:24 weeksenhanced_encryptionyesSafety Issue: Proportion of sildenafil subjects with a 50% or greater decrease from baseline in mean sperm concentration at 6 months (LOCF), compared to placebo and vardenafil after repeated usedate_rangeTime Frame:24 weeksenhanced_encryptionyesSafety Issue: Washington, DC - The FDA gave approval yesterday to vardenafil (Levitra®, Bayer and Glaxo Smith Kline), an oral erectile-dysfunction drug that works through the same mechanism as sildenafil (Viagra®, Pfizer). Like sildenafil, vardenafil can seriously affect blood pressure and should not levitra 40 mg online be taken by those on alpha blockers or nitrates. The recommended dose is 10 mg taken one hour before sexual activity, with 20-, 5.0-, and 2.5-mg doses available.

Optimal Use of Levitra Tablets

Professional resources

The FDA warns that men whose underlying cardiovascular status makes sexual activity inadvisable should not take vardenafil. Patients who have suffered an MI or stroke within the last six months or have hypotension or hypertension, unstable angina, severe liver impairment, end-stage renal disease requiring dialysis, or retinitis pigmentosa should not take the drug. "Today's approval of Levitra means there is now an important alternative in the treatment of erectile dysfunction," said Colin J Foster, president, Bayer Pharmaceuticals Corporation, in a press release. The drug will be comarketed by Glaxo Smith Kline and Bayer, and Bloomberg News reports packaging will feature the "Levitra flame" to help distinguish the round orange pills from cheap levitra oral jelly online Viagra's now-famous blue diamond-shaped ones. Both drugs are likely to soon have a third competitor stateside. "Today's approval of Levitra means there is now an important alternative in the treatment of erectile dysfunction," said Colin J Foster, president, Bayer Pharmaceuticals Corporation, in a press release. The drug will be comarketed by Glaxo Smith Kline and Bayer, and Bloomberg News reports packaging will feature the "Levitra flame" to help distinguish the round orange pills from cheap levitra oral jelly online Viagra's now-famous blue diamond-shaped ones. Both drugs are likely to soon have a third competitor stateside.

Levitra’s Manufacturing Excellence

Achieving treatment optimization with sildenafil citrate (Viagra(R)) in patients with erectile dysfunction

Eli Lilly & Co and Icos Corporation intend to introduce tadalafil (Cialis®), another phosphodiesterase inhibitor, to the US market later this year.

Ingredient	Quantity per tablet	Function
Vardenafil	20 mg	Active PDE5 inhibitor
Microcrystalline cellulose	-	Binder and filler
Lactose	-	Filler
Magnesium stearate	-	Lubricant
Hydroxypropyl methylcellulose	-	Coating agent
Titanium dioxide	-	White pigment for coating

Tadalafil and vardenafil have both been approved in Europe.

Where to participate

"Balancing the Pill Bottle: Unveiling the Pros and Cons of Deregulating Non-Essential Drug Prices in Pakistan"

Currently, there have been no head-to-head trials comparing effectiveness of the three drugs. A fourth oral erectile-dysfunction drug, apomorphine (Uprima®, TAP Pharmaceuticals), has been approved in Europe, and TAP Pharmaceuticals applied to the FDA for its approval at the end of 2002. It is a dopamine receptor agonist and works through an entirely different mechanism. Although the drug received the support of an FDA advisory panel in April 2000 (as reported by heartwire ), TAP Pharmaceuticals withdrew apomorphine's new drug application soon after, due to concerns that it caused fainting spells.

Storage Condition	Details
Temperature	Store below 30°C (86°F)
Light Protection	Keep in a dry, opaque container
Humidity	Avoid moisture exposure
Out of reach of children	Yes

It resubmitted the drug late last year after further studies. Cite this: FDA approves new erectile dysfunction drug - Medscape - Aug 20, 2003. aDepartment of Urology and Center for Sexual and Reproductive Health, Aristotle University of Thessaloniki, 77 Mitropoleos str., 546 22 Thessaloniki, Greece DOI: 10.1016/j.eururo.2004.01.014 External LinkAlso available on ScienceDirect External Link Vardenafil for Treatment of Men With Erectile Dysfunction: Efficacy and Safety in a Randomized, Double-Blind, Placebo-Controlled Trial Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study Influence of age on the efficacy and safety of vardenafil, a novel phosphodiesterase-5 inhibitor, for the treatment of erectile dysfunction The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction Achieving treatment optimization with sildenafil citrate (Viagra(R)) in patients with erectile dysfunction The potential value of erectile dysfunction inquiry and management Hellstrom, W.